Microbiotica is transforming personalised medicine with leading microbiome science, identifying gut bacteria linked to patient phenotype with unprecedented precision for the discovery of novel microbiome-based medicines and biomarkers of drug response.
Microbiotica was spun out of Trevor Lawley's Lab at the Wellcome Sanger Institute and is founded on a unique pipeline for culturing and genomically characterising the entirety of the bacteria in the human gut for the first time. It has the world's largest microbiome genome database and culture collection, a suite of translational in vitro and animal models, and state of the art bioinformatics and AI. The company has a focus on IBD and Immuno-Oncology, and a program in C. difficile which is spearheading innovation in development of live bacterial products.